Evaluation of the efficacy and safety of text messages targeting adherence to cardiovascular medications in secondary prevention: the txt2heart Colombia randomised controlled trial (Preprint)

Background: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in the world. Prevalence is estimated at around 100 million patients worldwide. There is evidence that antiplatelet agents and antihypertensive medication reduce the risk of new vascular events in this population, but treatment adherence is very low. Objective: We developed an intervention based on behavioral modification techniques delivered via mobile short message services (SMS) to increase the adherence to pharmacologic treatment on patients with prior history of ASCVD. Methods: We conducted a randomized controlled clinical trial for patients with a prior diagnosis of cardiovascular event such as acute myocardial infarction, unstable angina, cerebrovascular disease or peripheral artery disease in one centre in Colombia. Patients randomized to the intervention arm were assigned to receive SMS daily for the first 4 weeks, five SMS on week 5: three SMS per week from week 6, and one SMS from 8th week until 52nd week. Patients in the control arm received a monthly SMS reminding them of the next study appointment, requesting information about changes in phone number, thanking them for participating in the study and reminding them of the importance of the study. Primary endpoint was change in Low Density Lipoprotein-Cholesterol (LDL-C) and the secondary endpoints were change in thromboxane B2 levels, heart rate, systolic and diastolic blood pressure. Medication adherence was measured with the Medication Adherence Report Scale (MARS 5), mortality and new cardiac hospitalization were assessed at one year end point. A logistic regression analysis and bivariate testing was performed. Results: Nine hundred and thirty patients were randomized, 805 (87%) completed follow up, and were analyzed for the primary endpoint. There was no difference between arms in change of LDL-C at 12 months (P=.41). or for any of the secondary outcomes. No adverse events were reported. Conclusions: In our study we did not find evidence that a behavior modification intervention delivered by SMS improved LDL-C, blood pressure levels or adherence at 12 months. More research is needed to evaluate whether different SMS strategies including personalized messages and with different timing are effective; future studies should include mixed methods to understand better why, for whom and in which context (e.g. health system, social environment) SMS interventions work (or not) to improve adherence in patients with ASCVD. Clinical Trial: Clinicaltrial.gov NCT03098186. Date of registration: March 31st 201

Relationship between disease activity status or clinical response and patient-reported outcomes in patients with non-radiographic axial spondyloarthritis: 104-week results from the randomized controlled EMBARK study

Background We assessed the external validity of composite indices Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Assessment in SpondyloArthritis international Society (ASAS) 40 response (ASAS40) by evaluating the correlations between the changes in some patient reported outcomes (PROs) for patients with non-radiographic axial spondyloarthritis (nr-axSpA) and the changes in the scores of the composite indices. Methods This was a post-hoc analysis of data from the EMBARK study in patients with nr-axSpA treated with etanercept. PROs were grouped according to ASDAS status (inactive [= 1.3 to = 2.1 to 3.5]), patient achievement of > 50% improvement in BASDAI (BASDAI50 responders), and > 40% improvement in ASAS (ASAS40 responders) at 104 weeks. Analyses were conducted on observed cases available at Week 104. Changes in PROs from Baseline to Week 104 were assessed using analysis of covariance with adjustment for baseline with linear contrast. Results Higher ASDAS disease activity at 104 weeks was associated with lower long-term improvement from baseline in PROs (e.g., total back pain [visual analog scale, cm (95% confidence interval): - 4.58 (- 4.95, - 4.21), - 3.86 (- 4.28, - 3.43), - 2.15 (- 2.68, - 1.61), and 1.30 (- 0.51, 3.12) for inactive, low, high, and very high ASDAS disease activity, respectively; Multidimensional Fatigue Inventory (MFI) general fatigue: - 4.77 (- 5.70, - 3.84), - 2.96 (- 4.04, - 1.87), - 1.00 (- 2.32, 0.31), and 2.14 (- 2.10, 6.38); all p < 0.001)]. BASDAI50 non-responders had less improvement in PROs from Baseline to Week 104 vs. responders (e.g., total back pain: - 1.61 (- 2.05, - 1.18) vs. -4.43 (- 4.69, - 4.18); MFI general fatigue: - 0.01 (- 1.12, 1.09) vs. -4.30 (- 4.98, - 3.62); all p < 0.001). ASAS40 non-responders also had less improvement in PROs from Baseline to Week 104 vs. responders (e.g., total back pain: - 1.91 (- 2.30, - 1.52) vs. -4.75 (- 5.05, - 4.46); MFI general fatigue: - 0.63 (- 1.56, 0.30) vs. -4.64 (- 5.37, - 3.91); all p < 0.001). Conclusion Composite indices are valid for monitoring treatment response and adequately reflect treatment-related changes experienced by patients with nr-axSpA.Pathophysiology and treatment of rheumatic disease

Better Health-Related Quality of Life and Work Capacity in Patients Achieving Inactive Disease and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis

Pathophysiology and treatment of rheumatic disease

Vasculitis de grandes y medianos vasos. Características epidemiológicas, clínicas y paraclínicas

IP 2104-10-005-92Reumatologia. -- Vol. 12, no 2. -- (mar.-abr. 1997); p. 87-95.-- ISSN 01868969. -- Asociacion entre;Antonio Iglesias Gamarra. ... [et. al]. -- En: Revista Mexicanade Reumatologia. -- Vol. 10, no 4. --;anticuerpos contra el citoplasma de los neutrofilos (ANCA)y artritis reumatoide complicada con vasculitis /;(jul.-ago. 1994); p. 105-112. -- ISSN 01868969. -- Sindrome pulmon-riñon en lupus eritematoso sistemico.;Reporte de casos / Antonio Iglesias Gamarra. ... [et. al].--En: RevistaMexicana de Reumatologia. -- Vol.;Universidad Nacional de Colombia. -- Vol. 45, no 1. -- (1997);p. 16-20. -'- Enfermedad de buerger en el;Hospital San Juan de Dios / Antonio Iglesias Gamarra. ...[et.al]. -- En:Acta Medica Colombiana. -- Vol. 22,;no 3. -- (may.-jun. 1997); p. 125-131. -- Sindrome antifosfolipido cofactor / Antonio Iglesias Gamarra. ...;[et. al]. -- En: Acta Medica Colombiana. -- Vol. 22, no 4.--(jul.-ago. 1997); p. 188-198. -- Enfermedad de;Kawasaki y fenomeno de raynaud en un paciente de 15 años de edad/ AntonioIglesias Gamarra. ... [et. al]. --;En: Acta Medica Colombiana. -- Vol. 20, no 5. -- (sep.-oct. 1995); p. 241-244. -- Descripcion de un grupo de;pacientes con poliserositis como manifestacion temprana delupuseritematoso sistemico / Antonio Iglesias;Gamarra. ... [et. al]. -- En: Acta Medica Colombiana. -- Vol.22, no 2. --(mar.-abr. 1997); p. 78-84. --;Arteritis de takayasu en Colombia / Antonio Iglesias Gamarra.... [et. al]. -- En: Acta Medica Colombiana. --;Vol. 22, no 2. -- (mar.-abr. 1997); p. 85-92. -- Takayasuarteritis in Colombia / Antonio Iglesias Gamarra.;... [et. al]. -. En: International Journal of Cardiology.'-- Vol. 66. (1998); p. 73-79. -- Buerger's disease;at the San Juan de Dios Hospital, Santa fe de Bogotá, Colombia/Antonio Iglesias Gamarra. ... [et. al]. -- En;: International Journal of Cardiology. -- Vol. 66. (1998).--Vasculitis granulomatosa centrofacial: estudio;10, no 6. -- (nov.-dic. 1995); p. 185-194. -- ISSN 01868969. --Arterial fibrodysplasia causing occlusive;vascular disease simulating primary vasculitis / Antonio Iglesias Gamarra.... [et. al]. -- En: Revista de;Investigacion Clinica. -- Vol. 46, no 1. -- (ene.-feb. 1994);p.67-71. --ISSN 00348376. -- Un caso de lupus;asociado a mucinosis papulonodular / Antonio Iglesias Gamarra.... [et. al]. -- En: Revista de Investigacion;Clinica. -- Vol. 46, no 1. -- (ene.-feb. 1994); p. 63-66.'-- ISSN 00348376. -- Buerger's disease in the San;Juan de Dios hospital in Bogotá / Antonio Iglesias Gamarra. ...[et. al].'-- en: American College of;Rheumatology. -- Vol. 40, no 9. -- (Sep. 1997); p. 167. --Takayasu arteritis in Colombia / Antonio Iglesias;Gamarra. ... [et. al]. -- En: American College of Rheumatology.-- Vol. 40, no 9. -- (Sep. 1997); p. 169. --;Las Anexinas / Antonio Iglesias Gamarra. ... [et. al]. --En:Revista Colombiana de Reumatologia. -- Vol. 3,;no 1. -- (1996); p. 7-15. -- Asociacion de esclerosis sistemicay enfermedad de graves / Antonio Iglesias;Gamarra. ... [et. al]. -- En: Revista Colombiana de Reumatologia. -- Vol.3, no 1. -- (1996); p. 35-38. --;Criterios diagnosticos y clasificatorios de las enfermedades reumaticas /Antonio Iglesias Gamarra. ... [et.;al]. -- En: Revista Colombiana de Reumatologia. -- Vol. 4,no4.'-- (1997); p. 180-194. -- Vasculitis:;analisis de 12.683 protocolos de autopsia. Estudio de 34 casos/Antonio Iglesias Gamarra. ... [et. al]. --;En: Revista de la facultad de medicina Universidad Nacional deColombia. -- Vol. 44, no 2. -- (1996); p.;Revista Colombiana de Reumatologia. -- Vol. 5, no 1. -- (1998);p. 18-26.'-- Compromiso vascular en La;encefalitis herpetica / Antonio Iglesias Gamarra. ... [et.al].'-- en: Revista de la facultad de medicina;'-- Polyarticular sporothrix schenckii infection in an immunocompetent host: report f a case and review of the;literature / Antonio Iglesias Gamarra. ... [et. al]. -- En: Journal of clinical rheumatology. -- Vol. 2, no 4.; (Aug. 1996); p. 215-220. -- ISSN 1076-1608. -- Esclerosis sistemica progresiva sine escleroderma y;calcinosis universalis como manifestacion inicial / Antonio Iglesias Gamarra. ... [et. al]. -- En: Revista;Mexicana de Reumatologia. -- Vol. 9, no 3. -- (may.-jun. 1994);p. 129-137. -- ISSN 01868969. --;polineuropatia con compromiso de los cuatro miembros. Unaformade presentacion inusual de la panarteritis;75-80. -- Causas de muerte en lupus eritematoso sistemico:estudio de necropsias en 27 pacientes del Hospital;San Juan de Dios / Antonio Iglesias Gamarra. ... [et. al].--En: RevistaColombiana de Reumatologia. -- Vol.;4, no 3. -- (1997); p. 144-147. -- Sindrome de sjogren primario:Estudio prospectivo para conocer las;caracteristicas clinicas en nuestro medio / Antonio Iglesias Gamarra. ...[et. al]. -- En: Revista Colombiana;de Reumatologia. -- Vol. 4, no 3. -- (1997); p. 126-130. -'- anticuerpos contra citoplasma de neutrofilo;(ANCAs) en lupus eritematoso sistemico y artritis reumatoidea/Antonio Iglesias Gamarra. ... [et. al]. -- En:;nodosa / Antonio Iglesias Gamarra. ... [et. al]. -- En: RevistaMexicana de Reumatologia. -- Vol. 9, no 6. --;(nov.-dic. 1994); p. 199-205. -- ISSN 01868969. -- Linfomaangiocentrico de la linea media. Informe de tres;casos y revision de la literatura / Antonio Iglesias Gamarra.... [et al].'-- en: Revista Mexicana de;ARTICULO(S) EN REVISTA: Comment on transient osteoporosisof thehip / Antonio Iglesias Gamarra. ... [et.;al]. -- En: Journal of clinical rheumatology. -- Vol. 3, no 6.-- (Dic. 1997); p. 375-378. -- ISSN 10761608.;de seis casos y propuesta para su clasificacion / AntonioIglesias Gamarra. ... [et. al]. -- En: Biomedica. --;Vol. 14. -- (1994); p. 90-104. -- Analisis historico de las vasculitis, suclasificacion y propuesta para su;entendimiento / Antonio Iglesias Gamarra. ... [et. al]. --En:Biomedica.-- Vol. 13, no 1. -- (1993); p.;32-56. -- Surrogate markers of disease activity in patients withtakayasuarteritis a preliminary report from;the international network for the study of the systemic vasculitides (INSSYS) / Gary S. Hoffman, Alaa E. Ahmed;. -- En International Journal of Cardiology. -- Vol. 66, sup.1.'-- (1998); p. 191-194

Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients

BACKGROUND: The efficacy and safety of prolonging prophylaxis for venous thromboembolism in medically ill patients beyond hospital discharge remain uncertain. We hypothesized that extended prophylaxis with apixaban would be safe and more effective than short-term prophylaxis with enoxaparin. METHODS: In this double-blind, double-dummy, placebo-controlled trial, we randomly assigned acutely ill patients who had congestive heart failure or respiratory failure or other medical disorders and at least one additional risk factor for venous thromboembolism and who were hospitalized with an expected stay of at least 3 days to receive apixaban, administered orally at a dose of 2.5 mg twice daily for 30 days, or enoxaparin, administered subcutaneously at a dose of 40 mg once daily for 6 to 14 days. The primary efficacy outcome was the 30-day composite of death related to venous thromboembolism, pulmonary embolism, symptomatic deep-vein thrombosis, or asymptomatic proximal-leg deep-vein thrombosis, as detected with the use of systematic bilateral compression ultrasonography on day 30. The primary safety outcome was bleeding. All efficacy and safety outcomes were independently adjudicated. RESULTS: A total of 6528 subjects underwent randomization, 4495 of whom could be evaluated for the primary efficacy outcome--2211 in the apixaban group and 2284 in the enoxaparin group. Among the patients who could be evaluated, 2.71% in the apixaban group (60 patients) and 3.06% in the enoxaparin group (70 patients) met the criteria for the primary efficacy outcome (relative risk with apixaban, 0.87; 95% confidence interval [CI], 0.62 to 1.23; P=0.44). By day 30, major bleeding had occurred in 0.47% of the patients in the apixaban group (15 of 3184 patients) and in 0.19% of the patients in the enoxaparin group (6 of 3217 patients) (relative risk, 2.58; 95% CI, 1.02 to 7.24; P=0.04). CONCLUSIONS: In medically ill patients, an extended course of thromboprophylaxis with apixaban was not superior to a shorter course with enoxaparin. Apixaban was associated with significantly more major bleeding events than was enoxaparin. (Funded by Bristol-Myers Squibb and Pfizer; ClinicalTrials.gov number, NCT00457002.)

Ezetimibe added to statin therapy after acute coronary syndromes

BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. METHODS: We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization ( 6530 days after randomization), or nonfatal stroke. The median follow-up was 6 years. RESULTS: The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P = 0.016). Rates of pre-specified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. CONCLUSIONS: When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit

Vorapaxar in the secondary prevention of atherothrombotic events

Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)